Drug Products, Including Biological Products, that Contain Nanomaterials

On 21 April 2022 the FDA published the final guidance for industry on drug products with nanomaterials.

Nanotechnology can be used in a broad array of FDA-regulated products, such as human drug products, including those that are biological products. Nanotechnology may be used to create drug products in which nanomaterials (as explained in section II of this document), serve a variety of functions, as active ingredients or inactive ingredients, including carriers loaded with an active ingredient. The inclusion of such materials may result in product attributes that differ from those of products that do not contain such materials, and thus may merit particular examination. This document provides guidance on the development of human drug products, including those that are biological products, in which a nanomaterial is present in the finished dosage form.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /